ReviewWorld journal of clinical oncology2017
Multidisciplinary approach of colorectal cancer liver metastases.
Review in World journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Missing colorectal liver metastases: the surgical challenge.Langenbeck's archives of surgery · 2021Pooled it
- Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2018Trial
- Assessing the Impact of Multidisciplinary Team (MDT) Care on Patients with Liver Cancer/Cirrhosis: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2025Review
- A predictive model to identify optimal candidates for surgery among patients with metastatic colorectal cancer.Frontiers in oncology · 2025Article
- Role of Coagulation Factors in Hepatocellular Carcinoma: A Literature Review.Life (Basel, Switzerland) · 2024Review
- Liver metastases: The role of magnetic resonance imaging.World journal of gastroenterology · 2023Review
- Article
- Primary tumor resection in colorectal cancer patients with unresectable distant metastases: a minireview.Frontiers in oncology · 2023Review
- Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases.Hepatic oncology · 2022Article
- Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies.Clinical and translational science · 2021Observational
- Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- What is the optimal number of neoadjuvant chemotherapy cycles for resectable colorectal liver oligometastases?Annals of translational medicine · 2021Article
- Prognostic factors and therapeutic effects of different treatment modalities for colorectal cancer liver metastases.World journal of gastrointestinal oncology · 2020Article
- Article
- Article
- "Small-for-Flow" Syndrome: Concept Evolution.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Review
- Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study.Journal of cancer research and clinical oncology · 2020Observational
- Transarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: What every interventional radiologist should know.European journal of radiology open · 2020Review
- Article
- Hepatic arterial infusion of irinotecan and EmboCeptClinical & experimental metastasis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large bowel cancer is a worldwide public health challenge. More than one third of patients present an advanced stage of disease at diagnosis and the liver is the most common site of metastases. Selection criteria for early diagnosis, chemotherapy and surgery have been recently expanded. The definition of resectability remains unclear. The presence of metastases is the most significant prognostic factor. For this reason the surgical resection of hepatic metastases is the leading treatment. The most appropriate resection approach remains to be defined. The two step and simultaneous resection processes of both primary and metastases have comparable survival long-term outcomes. The advent of targeted biological chemotherapeutic agents and the development of loco-regional therapies (chemoembolization, thermal ablation, arterial infusion chemotherapy) contribute to extend favorable results. Standardized evidence-based protocols are missing, hence optimal management of hepatic metastases should be single patient tailored and decided by a multidisciplinary team. This article reviews the outcomes of resection, systemic and loco-regional therapies of liver metastases originating from large bowel cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.